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Abstract
Kaiso is a BTB/POZ transcription factor that is ubiquitously expressed in multiple cell types and functions as a transcriptional
repressor and activator. Little is known about Kaiso expression and localization in breast cancer. Here, we have related
pathological features and molecular subtypes to Kaiso expression in 477 cases of human invasive breast cancer. Nuclear
Kaiso was predominantly found in invasive ductal carcinoma (IDC) (p=0.007), while cytoplasmic Kaiso expression was linked
to invasive lobular carcinoma (ILC) (p=0.006). Although cytoplasmic Kaiso did not correlate to clinicopathological features,
we found a significant correlation between nuclear Kaiso, high histological grade (p=0.023), ERa negativity (p=0.001), and
the HER2-driven and basal/triple-negative breast cancers (p=0.018). Interestingly, nuclear Kaiso was also abundant in
BRCA1-associated breast cancer (p,0.001) and invasive breast cancer overexpressing EGFR (p=0.019). We observed
a correlation between nuclear Kaiso and membrane-localized E-cadherin and p120-catenin (p120) (p,0.01). In contrast,
cytoplasmic p120 strongly correlated with loss of E-cadherin and low nuclear Kaiso (p=0.005). We could confirm these
findings in human ILC cells and cell lines derived from conditional mouse models of ILC. Moreover, we present functional
data that substantiate a mechanism whereby E-cadherin controls p120-mediated relief of Kaiso-dependent gene repression.
In conclusion, our data indicate that nuclear Kaiso is common in clinically aggressive ductal breast cancer, while cytoplasmic
Kaiso and a p120-mediated relief of Kaiso-dependent transcriptional repression characterize ILC.
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Introduction
Kaiso was initially identified as a binding partner of the
adherens junction (AJ) complex member p120-catenin (p120) [1].
Kaiso is a member of the BTB/POZ-ZF (Broad complex,
Tramtrak, Bric a ´ brac/Pox virus and zinc finger) family of
transcription factors [2] consisting of approximately 60 BTB/
POZ-ZF members that include the cancer-associated B cell
lymphoma 6 (BCL6), lymphoma-related factor (LRF), and
hypermethylated in cancer (HIC1) genes (reviewed in [3]). Kaiso
(also known as zinc finger- and BTB domain-containing protein
33; ZBTB33) interacts with its target gene promoters via two
distinct mechanisms: via sequence-specific Kaiso binding sites
(KBS), consisting of the consensus sequence CTGCNA, or via
methylated CpG dinucleotides [4–7]. Although Kaiso can act as
a transcriptional activator [8], it mainly acts as a transcriptional
repressor by binding to the promoters of its target genes. This
interaction can be inhibited by p120 binding to a region flanking
Kaiso’s ZF motifs [1] and results in expression of distinct target
genes [9,10]. Kaiso has been shown to directly repress canonical
Wnt targets via TCF/LEF family members [11,12]. These target
genes include the matrix metalloprotease Matrilysin (aka MMP7),
CCND1, Siamois, Fos and Myc [4,12]. In addition, Kaiso can
regulate expression of Wnt11, a regulator of directed cell
movement and morphogenesis [10].
While there is data demonstrating a role for Kaiso in early
vertebrate development [12,13], data implicating Kaiso-mediated
regulation of gene transcription in cancer are scarce. Kaiso
expression and sub-cellular localization seems dynamic and highly
dependent on tumor type and micro-environmental conditions
[14,15]. Interestingly, Kaiso-null mice show resistance to intestinal
cancer characterized by a delayed onset of tumor development,
decreased tumor size, and prolonged survival when crossed with
APC
MIN/+ mice [16].
Loss of E-cadherin and subsequent disruption of AJ function is
strongly linked to breast cancer development and progression
(reviewed in [17]). Using tissue-specific and conditional mouse
models, we have established a causal relationship between early
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carcinoma (ILC) [18,19]. While b-catenin is rapidly degraded
upon loss of E-cadherin [20,21], p120 translocates and resides in
the cytosol [22], where it regulates anchorage-independent tumor
growth and metastasis through Mrip-dependent activation of the
Rock pathway [20]. In addition, cytoplasmic p120 has been
implicated in the acquisition of motility and invasiveness in E-
cadherin negative breast cancer [23,24]. The structure of p120
reveals a number of domains including a protein-protein in-
teraction Armadillo (Arm) domain consisting of 10 Armadillo
repeats. This domain mediates not only the interaction with
cadherins but also p120 binding to the transcriptional repressor
Kaiso, probably in a mutually exclusive manner [1].
Given the importance of p120 in the pathobiology of breast
cancer, and its regulation of Kaiso-mediated transcriptional
repression, we performed a comprehensive analysis of Kaiso
expression and localization to pathological features and molecular
subtypes in 477 cases of invasive breast cancer.
Materials and Methods
Patients
The study population was derived from the archives of the
Departments of Pathology of the University Medical Center
Utrecht, Utrecht, and the Radboud University Nijmegen Medical
Centre, Nijmegen, The Netherlands. These comprised 477 cases
of invasive breast cancer, including cases with a BRCA1 germ-line
mutation as previously described [25]. Histological grade was
assessed according to the Nottingham scheme, and mitotic activity
index (MAI) was assessed as before [26]. From representative
donor paraffin blocks of the primary tumors, tissue microarrays
were constructed by transferring tissue cylinders of 0.6 mm (3
cylinders per tumor) from the tumor area, determined by
a pathologist based on haematoxylin-eosin stained slides, using
a tissue arrayer (Beecher Instruments, Sun Prairie, WI, USA) as
described before [27]. The use of anonymous or coded leftover
material for scientific purposes is part of the standard treatment
contract with patients in The Netherlands [28]. Ethical approval
was not required.
Immunohistochemistry
Immunohistochemistry was carried out on 4 mm thick sections.
After deparaffination and rehydration, endogenous peroxidase
activity was blocked for 15 min in a 46 mM citric acid-100 mM
sodiumphosphate buffer solution pH5.8 containing 0.3% hydro-
gen peroxide. After antigen retrieval, i.e. boiling for 20 min in
10 mM citrate pH6.0 (Kaiso, p120, PR), Tris/EDTA pH9.0 (E-
cadherin, ERa, HER2), or Prot K (0.15 mg/ml, DAKO, Glostrup
Denmark) for 5 min at room temperature (EGFR), a cooling
period of 30 min preceded the primary antibody incubation.
Kaiso (clone 6F, Upstate, Billerica, MA, USA) [29] 1:100; E-
cadherin (clone 4A2C7, Zymed, Invitrogen, Breda, The Nether-
lands) 1:200; ERa (clone ID5, DAKO) 1:80; PR (clone PgR636,
DAKO) 1:25; HER2 (SP3, Neomarkers, Duiven, The Nether-
lands) 1:100 were diluted in PBS containing 1% BSA and
incubated for 1 h at room temperature. Primary antibodies against
p120 (cat 610134, BD Transduction Labs, San Diego, CA, USA)
1:500 and EGFR (clone 31G7, Zymed, Invitrogen) 1:30 were
diluted in PBS containing 1% BSA and incubated over night at
4uC. The signal was amplified using Powervision poly-HRP anti-
mouse, rabbit, rat (DPVO-HRP, Immunologic, Duiven, The
Netherlands) or the Novolink kit (Leica, Rijswijk, The Nether-
lands) (in the case of EGFR) and developed with diaminobenzi-
dine, followed by counterstaining with haematoxylin, dehydration
in alcohol, and mounting. Appropriate negative and positive
controls were used throughout.
Scoring of Immunohistochemistry
All scoring was done blinded to patient characteristics and
results of other staining by two independent observers. E-cadherin
and EGFR stainings were scored using the DAKO/HER2 scoring
system for membranous staining. Membranous scores 1+,2 +, and
3+ were considered positive, except for HER2 where only a score
of 3+ was considered positive. Kaiso staining was scored based on
localization and by counting the positive tumor nuclei, considering
samples with more than 5% positive tumor nuclei as positive.
Using thresholds of 1 or 10% for scoring nuclear accumulation as
positive did not change the results. p120 staining was scored based
on the localization as membranous or cytoplasmic.
Based on ERa, PR, and HER2 immunohistochemistry, tumors
were classified as luminal (ERa and/or PR positive), HER2-driven
(ERa-, PR-, HER2+), or basal-like/triple negative (ERa-, PR-,
HER2- with or without EGFR expression), the immunohisto-
chemical surrogate [30] of the original Sorlie/Perou classification
[31].
Statistics
Statistical analysis was performed using IBM SPSS Statistics
version 18.0 (SPSS Inc., Chicago, IL, USA). Associations between
categorical variables were examined using the Pearson’s Chi-
square test and associations between continuous variables using
the Student’s T-test. P-values ,0.05 were considered to be
statistically significant.
Cell Culture
Origin and culture of the mouse cell lines Trp53
D/D-3,
Trp53
D/D-4 and mILC-1 were described before [20]. ILC cell
line IPH-926 was cultured as described [32]. Human breast
cancer cell line MCF10a was obtained from ATCC (validated by
STR profiling), and cultured in DMEM/F12 (Invitrogen, Breda,
the Netherlands) supplemented with 10 mg/L insulin, 20 mg/L
EGF, 100 mg/L cholera toxin, and 500 mg/L hydrocortisone
(Sigma, Zwijndrecht, The Netherlands). All media contained
10% fetal calf serum, 100 IU/ml penicillin, and 100 mg/ml
streptomycin. All cell lines were maintained at 37uCi na5 %
CO2 humidified atmosphere.
Immunofluorescence
Cells were cultured on coverslips and fixed in methanol for 10
minutes, permeabilized using 0.3% Triton-X100/PBS and
subsequently blocked using 4% BSA (Roche, Woerden, The
Netherlands). Cover slips were incubated with mouse anti Kaiso
1:500 (clone 6F) in 4% BSA for 1 hour at room temperature.
Subsequently, cells were incubated in 4% BSA with goat-anti-
mouse Alexa 488 (1:600; Molecular Probes, Breda, The Nether-
lands) for 1 hour. Next, cells were incubated with TRITC-
conjugated mouse anti-p120 1:300 (clone 98/pp120, BD
Biosciences) overnight at 4uC. Cover slips were mounted using
Vectashield mounting medium (Vector Laboratories, Burlin-
game, CA, USA). Samples were analyzed by confocal laser
microscopy.
Luciferase Reporter Assay
Cells were cultured in 6-wells culture plates and grown to 40–
50% confluency. Next, cells were transfected with either 600 ng of
the Kaiso-specific reporter (pGL3-4XKBS), a mutated Kaiso
reporter (pGL3-4XKBS CAmut) or empty vector (pGL3-Control)
Kaiso Expression in Breast Cancer
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Leiden, The Netherlands) for normalization of transfection
efficiency, using Lipofectamine 2000 (Invitrogen) according to
manufactures instructions. In addition, cells were transfected with
400 ng effector plasmid consisting either of pC2-p120 isoform 1a,
pcDNA3.1-Kaiso or empty vector (pcDNA3.1). The transfection
mixture was added to the cells and incubated for 2.5 hours.
Followed by replacement of the transfection mixture by complete
medium.
Two days post-transfection cells were washed twice with PBS,
lysed by scraping in 200ml Passive Lysis Buffer (Promega) and
subjected to a freeze-thaw cycle. Cellular debris was spun down at
5,000 g at 4uC for 5 minutes and supernatants were collected.
Bioluminescence was measured in 50ml sample with Dual
Luciferase Reporter assay system (Promega) on a Lumat LB9507
Luminometer (Berthold Technologies, Vilvoorde, Belgium) ac-
cording manufactures instructions.
Results
Kaiso Expression in Normal Breast Epithelium and
Invasive Breast Cancer
In normal breast tissue, localization of Kaiso was observed in
the cytosol of both luminal and myoepithelial cells (Figure 1). We
detected nuclear Kaiso expression mainly in the luminal epithelial
cells, which was heterogeneous while the number of cells showing
nuclear Kaiso varied between ductal structures (5–35% of the
cells)(Figure 1).
Next, we set out to analyze Kaiso expression in invasive breast
cancer. We used a study population comprised of 312 (65.4%)
IDC, 130 (27.3%) ILC, and 35 (7.3%) invasive breast cancer cases
with other histology (Table 1). First, we scored absence or presence
of cytoplasmic expression of Kaiso, since this variable has recently
been linked to poor prognosis in non-small cell lung cancer
(NSCLC) [33]. Although cytoplasmic expression of Kaiso was
significantly different between the histological sub-types of breast
cancer (p=0.006), it was not associated with other clinicopatho-
logical features (Table 2 and Figure 2). Given that Kaiso functions
as a transcriptional repressor, we scored nuclear expression in our
breast cancer cohort. Since using thresholds of 1%, 5% or 10% for
scoring of nuclear accumulation resulted in identical outcome and
statistical significance (data no shown), we used 5% nuclear
localization as a positive cut-off percentage. IDC expressed
nuclear Kaiso more often than ILC (p=0.007; Table 3;
Figure 2), while exclusive cytoplasmic expression of Kaiso was
a common feature of ILC. In addition, no significant difference
was found between classical and pleomorphic lobular cancers
(p=0.237) (data not shown). For the other clinicopathological
Figure 1. Kaiso expression in normal breast epithelium. Sections were stained using immunohistochemistry for Kaiso (middle panel) or E-
cadherin (right panel). Kaiso expression in normal breast epithelium is heterogeneous; high nuclear expression (top row) versus only cytoplasmic
expression (bottom row) is found with equal frequency. Left panels show a haematoxylin and eosin (H&E) staining. Size bars equal 50 mm, in inserts
25 mm.
doi:10.1371/journal.pone.0037864.g001
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a MAI $13, had significantly more nuclear Kaiso than low-grade
tumors (p=0.023 and p=0.003, respectively), while no significant
differences were found for lymph node status and tumor size
(Table 3).
Nuclear Kaiso Expression and Molecular Subtypes of
Breast Cancer
Since Kaiso is implicated in transcriptional repression of specific
target genes, and our data indicated that nuclear Kaiso correlated
with histology and grading in our invasive breast cancer cohort, we
performed a cross-comparison between nuclear Kaiso expression
and the molecular subtypes of breast cancer. Nuclear Kaiso was
significantly enriched in the basal/triple negative and HER2-
driven breast cancers than luminal-type breast cancers (p=0.018;
Table 4). While we did not find differences in nuclear Kaiso
expression in the context of PR and HER2 (p=0.104 and
p=0.246, respectively), an inverse correlation between nuclear
Kaiso and ERa expression was detected (p=0.001) (Table 4).
Moreover, BRCA1-associated breast cancers showed a significantly
higher number of tumors expressing nuclear-localized Kaiso than
sporadic carcinomas (71,4% versus 29,3%, respectively; p,0.001,
Table 4).
Localization of Kaiso, EGFR and the Adherens Junction in
Breast Cancer
Expression of EGFR has been linked to prognosis in basal/
triple-negative breast cancer [34,35]. Because EGFR partly co-
localizes with the AJ [36], and EGF stimulation can modulate AJ
function through phosphorylation of Src, p120 and PKCd [37,38],
we determined whether EGFR expression correlated with levels of
membranous E-cadherin and nuclear Kaiso. Indeed, a strong
association between EGFR and E-cadherin (p,0.001) was
observed, which coincided with a higher prevalence of nuclear
Kaiso expression in EGFR-expressing breast cancers (p=0.019;
Table 4).
Kaiso was identified as a p120-binding partner in a yeast two-
hybrid screen, using p120 as bait [1]. Since then, several studies
indicated that p120 controls relief of Kaiso-mediated transcrip-
tional repression through binding and shuttling from and to the
cytosol [9,10]. Interestingly, this feature can be antagonized by E-
cadherin expression, a key determinant in the differential diagnosis
between IDC and ILC [39]. While approximately 90% of ILC
cases show loss of E-cadherin expression, the majority of IDC
cases have retained E-cadherin on the membrane [40–42]. Our
data indicated that IDC and ILC show significant differences in
cytoplasmic and nuclear Kaiso localization (Figure 2, Tables 3 and
4). The presence of AJs, i.e. membranous localization of E-
cadherin and p120, strongly correlated with high nuclear Kaiso
Figure 2. E-cadherin and p120 membrane localization correlates with nuclear Kaiso expression. IDC (left panels) and ILC (right panels)
were stained for E-cadherin, p120, and Kaiso using immunohistochemistry. Note the association between membrane-localized E-cadherin and p120,
and high nuclear Kaiso in IDC. In contrast, ILC is characterized by loss of E-cadherin, and expression of cytoplasmic p120, which correlates with
absence of nuclear Kaiso. Size bars equal 50 mm.
doi:10.1371/journal.pone.0037864.g002
Table 1. Clinicopathological characteristics of 477 invasive
breast cancer patients studied for the expression of Kaiso.
Feature Grouping N or value %
Age (years) Mean 60
Range 28 to 88
Histological type IDC 312 65.4
ILC 130 27.3
Other 35 7.3
Tumor size (cm) #2 207 43.4
.2 and #5 213 44.7
.5 50 10.5
Not available 7 1.4
Histological grade 1 85 17.8
2 165 34.6
3 208 43.6
Not available 19 4.0
MAI
# #12 241 50.5
$13 236 49.5
Lymph node status Negative* 229 48.0
Positive** 223 46.8
Not available 25 5.2
#per 2 mm
2.
*negative = N0 or N0(i+).
**positive = $N1mi (according to TNM 7
th edition, 2010).
doi:10.1371/journal.pone.0037864.t001
Table 2. Correlation of cytoplasmic Kaiso with
clinicopathological features in invasive breast cancer.
Cytoplasmic Kaiso expression
Feature N Negative Positive p-value
N (%) N (%)
Histological type
IDC 312 45 (14.4) 267 (85.6)
ILC 130 5 (3.8) 125 (96.2)
Other 35 5 (14.3) 30 (85.7) 0.006
Histological grade
1 85 12 (14.1) 73 (85.9)
2 163 16 (9.8) 147 (90.2)
3 207 25 (12.1) 182 (87.9) 0.585
Tumor size (cm)
#2 205 22 (10.7) 183 (89.3)
.2 and #5 213 29 (13.6) 184 (86.4)
.5 49 3 (6.1) 46 (93.9) 0.296
MAI (per 2 mm
2)
#12 238 29 (12.2) 209 (87.8)
$13 236 26 (11.0) 210 (89.0) 0.691
Lymph node status
Negative 229 28(12.2) 201(87.8)
Positive 223 25 (11.2) 198 (88.8) 0.737
doi:10.1371/journal.pone.0037864.t002
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nuclear Kaiso inversely correlated with cytoplasmic p120
(p=0.005), thus supporting the notion that loss of E-cadherin
and subsequent translocation of p120 to the cytosol may control
Kaiso localization.
To substantiate these findings, we analyzed expression of
Kaiso in MCF10a, a breast cancer cell line that expressed
membranous E-cadherin and p120. Furthermore, since our data
indicated that nuclear Kaiso and ILC were inversely correlated,
we also used immunofluorescence to examine Kaiso localization
in a recently generated and characterized bona fide human ILC
cell line; IPH-926 [32]. Although Kaiso expression was observed
in E-cadherin-expressing as well as in E-cadherin-mutant cells,
nuclear Kaiso was enriched in MCF10a cells, whereas IPH-926
virtually lacked nuclear Kaiso (Figure 3A). In addition, we
employed cell lines derived from conditional mouse models in
which E-cadherin and/or p53 were somatically inactivated [19].
In agreement with our findings in human cell lines, we could
detect nuclear Kaiso in an E-cadherin expressing and p53-
deficient mammary carcinoma cell line (Trp53
D/D-3), whereas
mouse ILC (mILC) cells mainly lacked nuclear Kaiso
(Figure 3B). Evidence that p120 could direct nuclear localization
of Kaiso was obtained by overexpressing p120 in Trp53
D/D-4
cells, which resulted in high cytoplasmic p120 and a reduction
in nuclear Kaiso (Figure 3C). To determine the effect of p120
overexpression on Kaiso-dependent transcriptional repression,
we performed reporter assays using a Kaiso reporter system
(containing 4 tandem-repeats of the consensus Kaiso Binding
Sequence; 4XKBS reporter). In line with our expression data,
we observed that Kaiso-dependent transcriptional repression was
significantly higher in Trp53
D/D-4 than in mILC-1 cells
(p=0.015; Figure 3D). Furthermore, transcriptional repression
of the 4XKBS reporter was attenuated by exogenous Kaiso
expression in mILC-1 cells (Figure 3D). Finally, we observed
that overexpression of p120 in Trp53
D/D-4 cells resulted in
decreased Kaiso-dependent transcriptional repression (Figure 3C
and 3D), consistent with a decrease in nuclear Kaiso expression.
These results support our findings in primary breast cancer
samples and indicate that p120 controls localization of Kaiso
and subsequent de-repression of Kaiso-dependent transcription
in breast cancer.
Table 3. Correlation of nuclear Kaiso with clinicopathological
features in invasive breast cancer.
Nuclear Kaiso expression
Feature N
Low
(,5%)
High
($5%) p-value
N (%) N (%)
Histological type
IDC 312 211 (67.6) 101 (32.4)
ILC 130 107 (82.3) 23 (17.7)
Other 35 25 (71.4) 10 (28.6) 0.007
Histological grade
1 85 67 (78.8) 18 (21.2)
2 165 125 (75.8) 40 (24.2)
3 208 136 (65.4) 72 (34.6) 0.023
Tumor size (cm)
#2 207 154 (74.4) 53 (25.6)
.2 and #5 213 149 (70.0) 64 (30.0)
.5 50 37 (74.0) 13 (26.0) 0.573
MAI (per 2 mm
2)
#12 241 188 (78.0) 53 (22.0)
$13 236 155 (65.7) 81 (34.3) 0.003
Lymph node status
Negative 229 168 (73.4) 61(26.6)
Positive 223 158 (70.9) 65 (29.1) 0.552
doi:10.1371/journal.pone.0037864.t003
Table 4. Correlation of nuclear Kaiso with the molecular
subtypes of breast cancer in invasive breast cancer.
Nuclear Kaiso expression
Feature N
Low
(,5%)
High
($5%) p-value
N (%) N (%)
Perou/Sorlie classification
Luminal 386 288 (74.6) 98 (25.4)
HER2-driven 19 13 (68.4) 6 (31.6)
Basal/Triple Negative 72 42 (58.3) 30 (42.7) 0.018
ERa
Positive 378 285(76.0) 93 (24.0)
Negative 99 58 (58.6) 41 (41.4) 0.001
PR
Positive 276 206 (74.6) 70 (25.4)
Negative 199 135 (67.8) 64 (32.2) 0.104
HER2
Positive 45 29 (64.4) 16 (35.6)
Negative 431 313 (72.6) 118 (27.4) 0.246
BRCA1
Mutation carrier 21 6 (28.6) 15 (71.4)
Sporadic 324 229 (70.7) 95 (29.3) 0.001
EGFR
Positive 80 49 (61.3) 31 (38.7)
Negative 395 293 (74.2) 102 (25.8) 0.019
doi:10.1371/journal.pone.0037864.t004
Table 5. Correlation between functional adherens junctions
and nuclear Kaiso expression in invasive breast cancer.
Nuclear Kaiso expression
Feature N
Low
(,5%)
High
($5%) p-value
N (%) N (%)
E-cadherin
Positive 327 220 (67.3) 107 (32.7)
Negative 121 97 (80.2) 24 (19.8) 0.008
p120
Membranous 320 214(66.9) 106 (33.1)
Cytoplasmic 139 114 (82.0) 25 (18.0) 0.001
doi:10.1371/journal.pone.0037864.t005
Kaiso Expression in Breast Cancer
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In addition to the established role of BTB-POZ-ZF
transcription factors in vertebrate development, increasing
evidence emerges that these factors can function as oncogenes
or tumor suppressors [43]. For instance, the BTB/POZ
promyelocytic leukemia zinc finger (PLZF) has been identified
as a translocation partner of the retinoic receptor alpha (RARa).
In this setting, PLZF confers oncogenic potential through fusion
to the hormone-binding domain of RARa, subsequent binding
to its target sites and local recruitment of histone deacetylases
[44]. Another well-studied BTB-POZ oncogene is BCL6,
a protein that exerts its pro-tumorigenic functions by repression
of target genes necessary for terminal B cell differentiation
[45,46]. In contrast, HIC1 is a candidate tumor suppressor that
is often found mutated or hypermethylated in human cancer
[47]. However, unlike PLZF, BCL-6 and HIC1, it remains
unclear whether Kaiso mislocalization or absence could drive
malignancy.
Kaiso could function as an oncogene or as a tumor suppressor
as it has been implicated in both transcriptional activation and
repression [4,8,13]. In colon cancer, Kaiso may regulate
methylation-dependent inhibition of tumor suppressors such as
CDKN2A by binding to its methylated promoter. As a consequence,
tumor cells are resistant to cell cycle arrest and chemotherapy-
mediated cell death [48]. Interestingly, genetic Kaiso ablation
results in a delay in intestinal tumorigenesis in the context of
APC
MIN/+ mice [16], which suggests that Kaiso may indeed
contribute to intestinal tumor progression through silencing of
tumor suppressors. Conversely, Kaiso has been strongly implicated
in regulation of Wnt signaling-related target genes [4,11,12,49,50].
Given its bi-modal nature of b-catenin-dependent regulation of
Figure 3. p120 and Kaiso localization in breast cancer cell lines. Human (A) and mouse (B) E-cadherin-expressing (top panels) and E-cadherin-
deficient (bottom panels) breast cancer cell lines were stained for p120 (left panels) and Kaiso (middle panels). Right panels depict the merge of Kaiso
(green) and p120 (red). Note the nuclear accumulation in MCF10a and Trp53
D/D-3 (arrows; also upper panels in C) versus cytoplasmic Kaiso expression
in human and mouse ILC (arrowheads; IPH-926 and mILC-1). (C) Overexpression of p120 in Trp53
D/D-4 cells resulted in decreased nuclear
accumulation of Kaiso (arrowheads; bottom panels) compared to untransfected Trp53
D/D-4, which shows predominantly nuclear Kaiso (arrows; upper
panels). Size bars equal 20 mm. (D) Kaiso-dependent reporter assay using the 4XKBS reporter in mILC-1 and Trp53
D/D-4 cells. Upon overexpression of
p120 in Trp53
D/D-4 cells, Kaiso-dependent gene repression is attenuated, whereas exogenous expression of Kaiso in mILC-1 increased gene
repression.
doi:10.1371/journal.pone.0037864.g003
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genes and Kaiso targets, the effects of Kaiso on tumor de-
velopment may be highly dependent on cell type and their
dependency on (canonical) Wnt signals. In lung cancer, cytoplas-
mic Kaiso was correlated with poor prognosis [33]. Here it was
proposed that the invasive phenotype of NSCLC might be
regulated by nuclear export of Kaiso, which was mediated by
phosphorylation of p120 isoform 3 [52]. Lung and other epithelial
tissue differ substantially from breast with respect to cadherin
expression and p120 function. For instance, condition p120
knockout in the skin, gastro-intestinal tract or oral cavity is
tolerated and induces hyperplasia or tumor formation [53–56]. In
contrast, p120 knock-out in the mammary gland is not tolerated
and leads to apoptosis and subsequent cell clearance (our
unpublished results), indicating that p120 family members may
play tissue-specific redundant roles, as has been suggested for d-
catenin in non-small-cell lung cancer [57].
In this study we have performed to the best of our knowledge,
the first comprehensive analysis of Kaiso expression in breast
cancer, using a tissue micro array (TMA)-based collection of 477
invasive breast cancer cases. Previous studies had already indicated
that localization of Kaiso may be highly variable depending on
tumor type and environmental context [14]. Our data indicate
that nuclear Kaiso expression correlates with the pathological and
phenotypical traits of specific breast cancer sub-types that are
linked to poor prognosis, i.e. high-grade, and basal/triple-negative
breast cancer. These tumors were also associated with high EGFR
expression, which is associated with worse prognosis for basal/
triple-negative breast cancers [34,35]. Our observation that
BRCA1-associated hereditary breast cancers often showed high
nuclear Kaiso, is in line with the finding that nuclear Kaiso is in
general associated with high grade, basal-like and EGFR positive
breast cancers. Since our data does not indicate differential E-
cadherin expression and localization between sporadic and
BRCA1-related invasive breast cancer, this cannot explain the
increase in nuclear Kaiso localization. Future research will have to
determine if and how other (p120-unrelated) events such as
promoter methylation of specific genes may recruit Kaiso to the
nucleus and initiate subsequent epigenetic silencing in BRCA1-
related invasive breast cancer. We have furthermore shown that
nuclear Kaiso correlated with the presence of membrane-localized
E-cadherin and p120, a finding that is in line with the reported
regulation of Kaiso by p120 [58]. In this scenario, p120 relieves
transcriptional repression by Kaiso and as such may control
shuttling of the p120/Kaiso complex to the cytosol [9]. Because
most IDC retain a membrane-localized E-cadherin/p120 com-
plex, our data confirmed this concept by showing that nuclear
Kaiso correlated with tumors expressing E-cadherin. Also, since
the basal-like and ERa negative high-grade tumors mainly reside
in the E-cadherin-expressing IDC cohort, it supports the notion
that p120 may regulate Kaiso distribution in breast cancer. The
mechanism of this needs to be further elucidated.
ILC is characterized by loss of the AJ complex through early
mutational inactivation of E-cadherin and subsequent trans-
location of p120 to the cytosol. If p120 were a major factor
controlling Kaiso distribution, one would expect that the absence
of nuclear Kaiso associated with ILC. Our data indeed conforms
to this hypothesis by showing that exclusive cytoplasmic Kaiso
expression is strongly correlated with the lobular phenotype.
Together, these findings suggest that genes may be differentially
regulated in IDC versus ILC as a result of differential Kaiso
localization. This notion may therefore partly explain the
differences in expression profiles that have been reported when
comparing IDC and ILC [59,60].
Recent data have indicated that phosphorylation of p120 can
increase its binding to Kaiso and induce inhibition of canonical
Wnt signaling [11]. It is well established that ILC expresses
cytoplasmic p120 and does not activate canonical Wnt signals
[20,21,61]. Although it is unclear if this mechanism controls
expression of Kaiso targets in ILC, it clearly emphasizes the
possible ramifications of Kaiso and its regulation by p120 in breast
cancer. Moreover, we have recently shown that cytoplasmic
translocation of p120 controls ILC tumor growth and metastasis
through Mrip-dependent regulation of Rock1 signaling, while IDC
does not appear to be contingent on these signals for anchorage-
independence [20]. We envisage that differential cadherin-catenin
localization in IDC and ILC and the signals that emanate from
p120 may not only explain the lobular phenotype, but probably
also control regulation of transcriptional regulation and cellular
biochemistry. Although Kaiso’s target genes in breast cancer are
unknown, our findings suggest that Kaiso may function as an
oncogene in IDC through inhibition of tumor suppressor gene
expression whereas in ILC, Kaiso might harbor tumor suppressor
functions by p120-mediated relieve of transcriptional repression of
oncogenic target genes. As such, it may have significant impact on
the development of personalized cancer care since it suggests that
the main breast cancer types may depend on diametrical
mechanisms for tumor progression.
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